Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12417042rdf:typepubmed:Citationlld:pubmed
pubmed-article:12417042lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:12417042lifeskim:mentionsumls-concept:C1335837lld:lifeskim
pubmed-article:12417042lifeskim:mentionsumls-concept:C0678222lld:lifeskim
pubmed-article:12417042lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:12417042lifeskim:mentionsumls-concept:C2826293lld:lifeskim
pubmed-article:12417042lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:12417042lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:12417042pubmed:issue10lld:pubmed
pubmed-article:12417042pubmed:dateCreated2002-11-5lld:pubmed
pubmed-article:12417042pubmed:abstractTextGlucose uptake and glycolytic metabolism are enhanced in cancer cells compared to normal cells and tissues. Increased expression of glucose transporter 1 (GLUT1) has been reported in human malignant cells. The aim of this study is to determine the expression of the facilitative glucose transporter protein GLUT1 in human breast carcinomas and a possible correlation between GLUT1 expression and clinical outcome including disease-free or overall survival. One hundred consecutive formalin-fixed, paraffin-embedded sections of invasive breast carcinomas were evaluated by means of immunohistochemical staining of GLUT1. Forty-seven (47%) of 100 breast carcinomas showed positive staining for GLUT1. Expression of GLUT1 correlated significantly with nuclear grade (P < 0.001), estrogen receptor status (P = 0.002), and progesterone receptor status (P = 0.001). The mean disease-free survival periods of GLUT1-positive and -negative patients were 47 +/- 2.4 months and 54.3 +/- 1.3 months, respectively (P = 0.017). The mean overall survival periods of GLUT1-positive and -negative patients were 48.7 +/- 2.2 and 56.1+/- 1.3 months, respectively (P = 0.043). In the multivariate analysis, disease-free survival correlated significantly with GLUT1, tumor size, and lymph node involvement (P = 0.043, P = 0.014, and P = 0.045, respectively). In analysis of overall survival, however, lymph node involvement, tumor size, and nuclear grade were statistically significant (P = 0.024, P = 0.023, and P = 0.003, respectively). Our data suggest that absence of GLUT1 expression significantly increases disease-free survival. These findings demonstrate that GLUT1 expression in breast carcinoma can be a marker of aggressive biological behavior and identifies a worse prognosis in breast carcinoma patients.lld:pubmed
pubmed-article:12417042pubmed:languageenglld:pubmed
pubmed-article:12417042pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12417042pubmed:citationSubsetIMlld:pubmed
pubmed-article:12417042pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12417042pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12417042pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12417042pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12417042pubmed:statusMEDLINElld:pubmed
pubmed-article:12417042pubmed:monthOctlld:pubmed
pubmed-article:12417042pubmed:issn0910-5050lld:pubmed
pubmed-article:12417042pubmed:authorpubmed-author:LeeHae...lld:pubmed
pubmed-article:12417042pubmed:authorpubmed-author:ParkYong...lld:pubmed
pubmed-article:12417042pubmed:authorpubmed-author:KangSung...lld:pubmed
pubmed-article:12417042pubmed:authorpubmed-author:ChunYi...lld:pubmed
pubmed-article:12417042pubmed:authorpubmed-author:HurMin HeeMHlld:pubmed
pubmed-article:12417042pubmed:authorpubmed-author:KimYee...lld:pubmed
pubmed-article:12417042pubmed:authorpubmed-author:HongSung...lld:pubmed
pubmed-article:12417042pubmed:authorpubmed-author:LeeJee HyunJHlld:pubmed
pubmed-article:12417042pubmed:authorpubmed-author:LeeSung...lld:pubmed
pubmed-article:12417042pubmed:issnTypePrintlld:pubmed
pubmed-article:12417042pubmed:volume93lld:pubmed
pubmed-article:12417042pubmed:ownerNLMlld:pubmed
pubmed-article:12417042pubmed:authorsCompleteYlld:pubmed
pubmed-article:12417042pubmed:pagination1123-8lld:pubmed
pubmed-article:12417042pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:meshHeadingpubmed-meshheading:12417042...lld:pubmed
pubmed-article:12417042pubmed:year2002lld:pubmed
pubmed-article:12417042pubmed:articleTitleClinical significance of glucose transporter 1 (GLUT1) expression in human breast carcinoma.lld:pubmed
pubmed-article:12417042pubmed:affiliationDepartment of Surgery, Samsung Cheil Hospital & Women's Healthcare Center, Sungkyunkwan University School of Medicine, 1-19, Mookjung-Dong, Chung-Ku, Seoul, Korea, 100-380.lld:pubmed
pubmed-article:12417042pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12417042lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12417042lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12417042lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12417042lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12417042lld:pubmed